| 201 |
18551039 | Common variation in the NOS1AP gene is associated with reduced glucose-lowering effect and with increased mortality in users of sulfonylurea. | 2008 Jul |
2 |
| 202 |
18571549 | Permanent neonatal diabetes mellitus caused by a novel homozygous (T168A) glucokinase (GCK) mutation: initial response to oral sulphonylurea therapy. | 2008 Jul |
1 |
| 203 |
18600596 | Replacing SUs with incretin-based therapies for type 2 diabetes mellitus: challenges and feasibility. | 2008 Jul |
2 |
| 204 |
18784090 | 10-year follow-up of intensive glucose control in type 2 diabetes. | 2008 Oct 9 |
1 |
| 205 |
18801852 | Exercise and glycemic control in diabetes: benefits, challenges, and adjustments to pharmacotherapy. | 2008 Nov |
1 |
| 206 |
19410163 | Overcoming patient barriers to initiating insulin therapy in type 2 diabetes mellitus. | 2008 |
2 |
| 207 |
17069922 | Factors associated with improvement of fasting plasma glucose level by mealtime dosing of a rapid-acting insulin analog in type 2 diabetes. | 2007 Mar |
1 |
| 208 |
17082235 | Sulfonylureas and glinides exhibit peroxisome proliferator-activated receptor gamma activity: a combined virtual screening and biological assay approach. | 2007 Feb |
1 |
| 209 |
17161222 | Thiazolidinediones increase hepatic insulin extraction in African Americans with impaired glucose tolerance and type 2 diabetes mellitus. A pilot study of rosiglitazone. | 2007 Jan |
1 |
| 210 |
17192350 | Transfer to sulphonylurea therapy in adult subjects with permanent neonatal diabetes due to KCNJ11-activating [corrected] mutations: evidence for improvement in insulin sensitivity. | 2007 Jan |
1 |
| 211 |
17213273 | Prevalence of permanent neonatal diabetes in Slovakia and successful replacement of insulin with sulfonylurea therapy in KCNJ11 and ABCC8 mutation carriers. | 2007 Apr |
2 |
| 212 |
17258675 | [Drug treatment of type 2 diabetes]. | 2007 Feb |
1 |
| 213 |
17316868 | Sulfonylurea and glinide reduce insulin content, functional expression of K(ATP) channels, and accelerate apoptotic beta-cell death in the chronic phase. | 2007 Sep |
3 |
| 214 |
17452235 | Sulfonylurea-responsive diabetes in childhood. | 2007 May |
1 |
| 215 |
17561795 | Comparison of once-daily glargine plus sulfonylurea with twice-daily 70/30 aspart premix in insulin-naive Japanese patients with diabetes. | 2007 Jun |
2 |
| 216 |
17594390 | Pioglitazone and sulfonylureas: effectively treating type 2 diabetes. | 2007 Jun |
4 |
| 217 |
17636829 | Interventions for latent autoimmune diabetes (LADA) in adults. | 2007 Jul 18 |
4 |
| 218 |
17652641 | A novel mutation causing DEND syndrome: a treatable channelopathy of pancreas and brain. | 2007 Sep 25 |
1 |
| 219 |
17890232 | Addition of biphasic, prandial, or basal insulin to oral therapy in type 2 diabetes. | 2007 Oct 25 |
1 |
| 220 |
17931842 | [Neonatal diabetes: a disease linked to multiple mechanisms]. | 2007 Nov |
1 |
| 221 |
17976204 | Glycaemic responsiveness to long-term insulin plus sulphonylurea therapy as assessed by sulphonylurea withdrawal. | 2007 Dec |
3 |
| 222 |
18078023 | A review of pioglitazone HCL and glimepiride in the treatment of type 2 diabetes. | 2007 |
1 |
| 223 |
18357954 | Overcoming patient barriers to initiating insulin therapy in type 2 diabetes mellitus. | 2007 |
2 |
| 224 |
16367882 | Effect of early addition of rosiglitazone to sulphonylurea therapy in older type 2 diabetes patients (>60 years): the Rosiglitazone Early vs. SULphonylurea Titration (RESULT) study. | 2006 Jan |
1 |
| 225 |
16380479 | Glibenclamide treatment recruits beta-cell subpopulation into elevated and sustained basal insulin synthetic activity. | 2006 Jan |
1 |
| 226 |
16425966 | Disproportionately elevated proinsulin levels in type 2 diabetic patients treated with sulfonylurea. | 2006 Jan |
5 |
| 227 |
16492219 | Effect of the oral hypoglycaemic sulphonylurea glibenclamide, a blocker of ATP-sensitive potassium channels, on walking distance in patients with intermittent claudication. | 2006 Mar |
1 |
| 228 |
16501671 | Comparison of lipid profiles and lipoprotein a levels in patients with type 2 diabetes mellitus during oral hypoglycemic or insulin therapy. | 2006 Feb |
2 |
| 229 |
16502763 | Antidiabetic medications in overdose: a comparison of the inquiries made to a regional poisons unit regarding original sulfonylureas, biguanides and insulin. | 2006 Feb |
1 |
| 230 |
16585812 | Anti-diabetic drug use and the risk of motor vehicle crash in the elderly. | 2006 Winter |
2 |
| 231 |
16631806 | Long-term efficacy of sulfonylureas: a United Kingdom Prospective Diabetes Study perspective. | 2006 May |
2 |
| 232 |
16706122 | [Variations of beta-cell early-phase insulin secretion in type 2 diabetic patients in different stages]. | 2006 Apr |
1 |
| 233 |
16800161 | Cost-effectiveness of rosiglitazone oral combination for the treatment of type 2 diabetes in Germany. | 2006 |
1 |
| 234 |
16873787 | Chromium picolinate supplementation attenuates body weight gain and increases insulin sensitivity in subjects with type 2 diabetes. | 2006 Aug |
1 |
| 235 |
16885550 | Switching from insulin to oral sulfonylureas in patients with diabetes due to Kir6.2 mutations. | 2006 Aug 3 |
3 |
| 236 |
16901797 | Metastatic malignant insulinoma in a patient with type 2 diabetes mellitus: case presentation and literature review. | 2006 Jul-Aug |
1 |
| 237 |
16925503 | Defining the genetic aetiology of monogenic diabetes can improve treatment. | 2006 Sep |
1 |
| 238 |
17003289 | Actions of glucagon-like peptide-1 on KATP channel-dependent and -independent effects of glucose, sulphonylureas and nateglinide. | 2006 Sep |
1 |
| 239 |
17020435 | Management of Type 2 diabetes: the role of incretin mimetics. | 2006 Oct |
1 |
| 240 |
17047922 | Improved motor development and good long-term glycaemic control with sulfonylurea treatment in a patient with the syndrome of intermediate developmental delay, early-onset generalised epilepsy and neonatal diabetes associated with the V59M mutation in the KCNJ11 gene. | 2006 Nov |
1 |
| 241 |
17087301 | [Management of blood glucose--target of the management and its practice]. | 2006 Nov |
1 |
| 242 |
17296510 | Diabetes and hypoglycaemia in young children and mutations in the Kir6.2 subunit of the potassium channel: therapeutic consequences. | 2006 Dec |
2 |
| 243 |
17491708 | Assessment of insulin sensitivity in adults with permanent neonatal diabetes mellitus due to mutations in the KCNJ11 gene encoding Kir6.2. | 2006 Spring |
1 |
| 244 |
15642492 | Effects of prolonged in vitro exposure to sulphonylureas on the function and survival of human islets. | 2005 Jan-Feb |
1 |
| 245 |
15694373 | Glimepiride enhances intrinsic peroxisome proliferator-activated receptor-gamma activity in 3T3-L1 adipocytes. | 2005 Mar 11 |
2 |
| 246 |
15816204 | Progressive decrease of proinsulin secretion in sulphonylurea-treated type 2 diabetes. | 2005 |
2 |
| 247 |
15912128 | Glibenclamide depletes ATP in renal proximal tubular cells by interfering with mitochondrial metabolism. | 2005 Aug |
1 |
| 248 |
15929679 | IRIS II study: intact proinsulin is confirmed as a highly specific indicator for insulin resistance in a large cross-sectional study design. | 2005 Jun |
1 |
| 249 |
15936468 | Efficacy of glimepiride in Japanese type 2 diabetic subjects. | 2005 Jun |
1 |
| 250 |
16026380 | Long-term effects of pioglitazone and metformin on insulin sensitivity in patients with Type 2 diabetes mellitus. | 2005 Aug |
2 |